Exact Sciences Gains 0.95% with 951% Volume Spike Hits 93rd in Trading Activity as Abbott Acquisition Nears

Market Snapshot

Exact Sciences (EXAS) closed Wednesday at $104.91, reflecting a 0.95% increase from its previous close of $103.92. The stock’s intraday range of $104.90 to $104.98 suggests limited volatility, with the price stabilizing near its opening level of $104.93. Trading volume surged to 20.7 million shares, a 951.37% spike compared to the average daily volume of 2.24 million shares. This elevated activity ranked EXAS at position 93 in overall trading volume on the day, underscoring heightened investor interest ahead of its impending acquisition by Abbott.

Key Drivers

The primary catalyst for EXAS’s price movement is the imminent closure of its $21 billion acquisition by Abbott Laboratories, set to finalize on March 23, 2026. Regulatory approvals and shareholder votes—finalized on March 19 and February 20, respectively—have eliminated key uncertainties, triggering a surge in trading activity as the market priced in the deal’s certainty. Abbott’s strategic move to enter the cancer screening and diagnostics sector through Exact Sciences’ flagship products, including Cologuard and Oncotype Dx, has positioned the transaction as a transformative growth opportunity. Analysts highlight that the acquisition aligns with Abbott’s long-term vision to expand into high-margin, high-growth diagnostics markets, a narrative that has bolstered confidence in the stock’s short-term trajectory.

The merger’s anticipated impact on market dynamics further supports EXAS’s performance. Exact Sciences’ portfolio of non-invasive cancer tests, such as Cologuard and Cancerguard, provides Abbott access to a $60 billion U.S. market for early cancer detection. This expansion into precision oncology and molecular diagnostics is expected to diversify Abbott’s revenue streams, offering a counterbalance to its traditional medical devices business. The deal’s projected $3 billion incremental sales contribution in 2026 and the company’s emphasis on “proactively shaping the portfolio to anticipate future medical needs” have reinforced investor optimism.

However, the transaction also carries inherent risks that may temper long-term enthusiasm. Exact Sciences’ trailing-12-month earnings per share (EPS) of -$1.10 and a beta of 1.44 indicate operational and volatility challenges. Additionally, the acquisition is expected to dilute 2026 adjusted EPS by 20¢, a factor that could weigh on post-merger performance. Despite these risks, the market’s reaction to the regulatory clearance—marked by a 951% surge in trading volume—suggests that investors are prioritizing the strategic value of the deal over near-term earnings pressures.

The broader healthcare sector’s focus on preventative care and early disease detection has amplified the acquisition’s appeal. Exact Sciences’ role in advancing non-invasive, accessible diagnostics aligns with global healthcare trends, particularly as cancer incidence rises. Abbott’s CEO, Robert Ford, emphasized the transaction’s potential to “make care more accessible and give people more control over their health,” a sentiment that resonates with investors seeking long-term value in healthcare innovation. The deal also underscores the sector’s shift toward consolidation, as larger players like Abbott seek to integrate cutting-edge technologies to maintain competitive advantages.

Finally, the economic impact of the acquisition on Wisconsin and Madison, where Exact Sciences is headquartered, has added a layer of regional optimism. The company employs 7,200 people globally, with half based in Wisconsin, and contributes $6–7 billion annually to the state’s GDP. Abbott’s commitment to maintaining Exact Sciences’ presence in Madison has alleviated concerns about job losses, reinforcing the deal’s positive reception among local stakeholders. This alignment of corporate strategy with regional economic interests further insulates the acquisition from potential backlash, contributing to the stock’s stable performance.

In summary, EXAS’s 0.95% gain and record trading volume reflect the market’s confidence in the Abbott acquisition’s strategic and financial merits. While risks such as EPS dilution and operational integration challenges remain, the deal’s alignment with healthcare trends, growth potential, and regional support position it as a defining event for Exact Sciences. Investors appear to be pricing in a successful transition into Abbott’s portfolio, with the stock’s performance likely to remain sensitive to pre-closing developments in the coming days.